
Opinion|Videos|May 23, 2025
Important Patient and Clinical Considerations When Choosing Therapy in RRMM Following CAR T Therapy
Author(s)Aimaz Afrough, MD, Natalia Neparidze, MD
Panelists discuss how selinexor offers convenient oral administration, bispecific antibodies provide high response rates but may present toxicity risks, and cytotoxic chemotherapy is effective for aggressive disease but carries significant adverse effects and risks.
Advertisement
Episodes in this series

Physician Summary: Advantages and Disadvantages of Available Treatment Options
Selinexor:
- Advantages:
- Oral administration allows for easier access and reduces the need for frequent clinic visits.
- Convenient for patients who may prefer oral therapy over intravenous options.
- Disadvantages:
- Can have adverse effects like nausea and fatigue.
- May require dose adjustments based on tolerance.
Bispecific Antibodies:
- Advantages:
- High response rates in patients, offering effective disease control.
- Available as off-the-shelf therapies, providing rapid access.
- Disadvantages:
- Potential for toxicity, including cytokine release syndrome and neurotoxicity.
- Access limitations due to the need for specialized administration and possible cost issues.
- Infection risk due to immune modulation.
Cytotoxic Chemotherapy:
- Advantages:
- Effective for aggressive disease with quick action in cytoreduction.
- Broad applicability in various clinical settings.
- Disadvantages:
- Associated with myelosuppression, renal dysfunction, and the potential for hospitalization due to adverse effects.
- T-cell suppression, which can impair responses to subsequent immunotherapies.
Key Takeaway: Each treatment has its own benefit-risk profile—selinexor offers convenience, bispecific antibodies deliver high response rates, and cytotoxic chemotherapy can be effective in aggressive disease, though each carries specific challenges in terms of toxicity and patient burden.
Advertisement
Related to this article

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.

China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.

An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.

Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.

Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.

The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
4
Dr Hoffmann on the Significance of Efficacy Data for Sonrotoclax Plus Zanubrutinib in MCL
5

